Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7291 | Carcinine ditrifluoroacetate |
| Highly selective H3 receptor antagonist (Ki values are 0.30, 365 and 3621 μM for H3, H2 and H1 receptors respectively). Acts as a natural antioxidant with hydroxyl radical scavenging and lipid peroxidase activities. | |
| BCC7292 | N20C hydrochloride |
| Selective, non-competitive NMDA receptor antagonist (IC50 = 5 μM); binds to the receptor-associated ion channel and prevents glutamate-induced Ca2+ influx. Displays neuroprotective activity in vivo. Brain-penetrant. | |
| BCC7293 | ABT 724 trihydrochloride |
| Potent dopamine D4 receptor partial agonist (EC50 = 12.4 nM; 61% efficacy vs. dopamine). Has no agonist activity at D2 receptors (EC50 > 10 μM). Selective in rats in vivo; produces penile erection following i.c.v. administration; increases intracavernosal pressure and potentiates the proerectile effects of sildenafil following s.c. administration. Displays minimal side effects. | |
| BCC7295 | (±)-HIP-B |
| Potent, non-competitive excitatory amino acid transporter (EAAT) blocker. Preferentially inhibits glutamate-induced [3H]D-aspartate release (IC50 = 1.2 μM) rather than [3H]L-glutamate uptake (IC50 = 16.9 μM). Moderately selective; displays no affinity for NMDA and metabotropic glutamate receptors, and low affinity for AMPA and kainate receptors (IC50 values are 35 and 45 μM respectively). | |
| BCC7299 | CI 976 |
| Selective acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor (IC50 = 0.073 μM). Lowers non-high density lipoprotein (HDL)-cholesterol and increases HDL-cholesterol concentrations in rats with pre-established dyslipidemia. Orally active. Also inhibits Golgi-associated LPL acyltransferase (LPAT) activity (IC50 = 15 μM). | |
| BCC7300 | GW 583340 dihydrochloride |
| Potent dual EGFR/ErbB2 tyrosine kinase inhibitor (IC50 values are 0.01 and 0.014 μM respectively). Selectively inhibits growth of human tumor cells overexpressing EGFR and ErbB2 (IC50 values are 0.11 μM for inhibition of HN5, N87 and BT474 tumor cell lines vs. > 30 μM for inhibition of non-tumor cell line HFF). Inhibits tumor growth in vivo by ~ 80% in a murine xenograft model following oral administration. | |
| BCC7301 | DMAB-anabaseine dihydrochloride |
| Partial agonist at α7-containing neuronal nicotinic receptors and antagonist at α4β2 and other nicotinic receptors. Displays specific cognition-enhancing effects; improves long-term memory in rats. | |
| BCC7307 | Ro 08-2750 |
| Non-peptide inhibitor of NGF that binds the NGF dimer (KD ~ 1 μM) possibly causing a conformational change. Selectively inhibits binding of NGF to p75NTR at submicromolar concentrations, and to both p75NTR and TrkA at concentrations > 5 μM. Prevents NGF-induced apoptosis in SK-N-MC cells. | |
